Holen Sie sich die Stockscreener-App
852.35
1.45%
-12.55
Handel nachbörslich:
853.00
0.65
+0.08%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt LLY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$864.90
Offen:
$869.55
24-Stunden-Volumen:
2.60M
Relative Volume:
0.76
Marktkapitalisierung:
$765.56B
Einnahmen:
$45.04B
Nettoeinkommen (Verlust:
$10.59B
KGV:
72.79
EPS:
11.71
Netto-Cashflow:
$414.30M
1W Leistung:
+3.63%
1M Leistung:
-5.48%
6M Leistung:
-7.81%
1J Leistung:
+10.25%
1-Tages-Spanne:
$847.92
$874.92
1-Wochen-Bereich:
$819.50
$874.92
52-Wochen-Spanne:
$711.40
$972.53
Lilly Eli Co Stock (LLY) Company Profile
Firmenname
Lilly Eli Co
Sektor
Telefon
(317) 276-2000
Adresse
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Vergleichen Sie LLY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
852.35 | 765.56B | 45.04B | 10.59B | 414.30M | 11.71 |
|
ABBV
Abbvie Inc
|
201.34 | 355.44B | 56.33B | 4.28B | 17.83B | 2.40 |
|
JNJ
Johnson Johnson
|
161.02 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
73.60 | 334.39B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
87.87 | 235.20B | 64.17B | 17.12B | 18.10B | 6.73 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-10 | Fortgesetzt | BofA Securities | Buy |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-09-13 | Fortgesetzt | Citigroup | Buy |
| 2024-08-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Herabstufung | DZ Bank | Buy → Hold |
| 2024-02-16 | Bestätigt | Morgan Stanley | Overweight |
| 2023-12-21 | Herabstufung | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-20 | Fortgesetzt | UBS | Buy |
| 2023-08-09 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-26 | Bestätigt | Citigroup | Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | UBS | Buy |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Eingeleitet | Jefferies | Hold |
| 2023-02-15 | Herabstufung | Societe Generale | Hold → Sell |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-09-22 | Hochstufung | UBS | Neutral → Buy |
| 2022-05-23 | Eingeleitet | SVB Leerink | Outperform |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-03-10 | Eingeleitet | Daiwa Securities | Outperform |
| 2022-01-21 | Hochstufung | DZ Bank | Hold → Buy |
| 2022-01-03 | Bestätigt | Bernstein | Mkt Perform |
| 2021-12-17 | Eingeleitet | Goldman | Neutral |
| 2021-12-16 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-16 | Bestätigt | BofA Securities | Buy |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-10-11 | Hochstufung | Berenberg | Hold → Buy |
| 2021-09-29 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-08-05 | Hochstufung | DZ Bank | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-06-24 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-12-10 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Mkt Perform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-09-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-04-21 | Herabstufung | UBS | Buy → Neutral |
| 2020-04-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2019-12-18 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-05-28 | Eingeleitet | Goldman | Buy |
| 2019-04-24 | Hochstufung | Edward Jones | Hold → Buy |
| 2019-04-11 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2019-01-23 | Eingeleitet | UBS | Buy |
| 2018-11-26 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-10-31 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Eingeleitet | Guggenheim | Buy |
| 2018-10-01 | Bestätigt | SunTrust | Buy |
| 2018-09-26 | Fortgesetzt | JP Morgan | Overweight |
Alle ansehen
Lilly Eli Co Aktie (LLY) Neueste Nachrichten
Lilly announces details of presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting - Quantisnow
Lilly Announces Details Of Presentations At 2025 American Association For Cancer Research (AACR) Annual Meeting - Marketscreener.com
Lilly Unveils Groundbreaking Cancer Drug Pipeline: Dual Phase 1 Programs Target KRAS and SMARCA4 Mutations - StockTitan
Global CEO Of Eli Lilly, World’s Pioneer Insulin Manufacturing Company, David Ricks Called On Union Minister Dr. Jitendra Singh To Discuss Strengthening Partnership, With A Focus On Insulin And NCD Therapies As Well As Biomanufacturing. - TRIPURA STAR NEWS
Eli Lilly GC Made Nearly $7.5M In 2024 - Law360
Bernstein reiterates Eli Lilly outperform with $1100 target By Investing.com - Investing.com UK
Organovo Announces Close of the Sale of FXR Program to Eli Lilly and Company - Quantisnow
Novo Nordisk follows Eli Lilly with its own ‘triple-G’ drug - STAT
Major Deal: Eli Lilly Acquires Organovo's FXR Program in Strategic Asset Purchase - StockTitan
Is Eli Lilly and Company (NYSE:LLY) The Best Stocks to Buy Now For the Long Term? - Insider Monkey
Eli Lilly Shares Rise Over 2% After Key Signal - Benzinga
UBS maintains Eli Lilly stock Buy rating, $1,100 price target By Investing.com - Investing.com Australia
5 Stocks That Could Be The Next Nvidia - Benzinga
Eli Lilly will soon release key data on its weight loss pill. Here's why it could be a game-changer - NBC Philadelphia
Eli Lilly’s Mounjaro targets India’s $150 billion weight-loss market amid rising diabetes crisis - CNBCTV18
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped - MSN
Was Jim Cramer Right About Eli Lilly and Company (LLY)? - Insider Monkey
Eli Lilly’s SWOT analysis: stock outlook strong despite challenges By Investing.com - Investing.com UK
Eli Lilly stock target holds at $1,020, Jefferies affirms Buy rating - Investing.com
UBS maintains Eli Lilly stock Neutral with $1100 target - Investing.com
UBS maintains Eli Lilly stock Neutral with $1100 target By Investing.com - Investing.com UK
UBS maintains Eli Lilly stock Buy rating, $1,100 price target - Investing.com India
Eli Lilly Unusual Options Activity - Benzinga
Is Eli Lilly and Company (LLY) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Is Ozempic maker Novo Nordisk losing to Eli Lilly in the obesity wars? - Proactive Investors UK
Sesame, America's Low-Cost Leader in Healthcare, Streamlines Access for Eligible Patients to Lilly's Obesity Medicine Zepbound - The Manila Times
Lilly, Novo expand DTC reach of obesity meds after compound win - Yahoo Finance
China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment' - MSN
Is Eli Lilly and Company (LLY) The Best Robinhood Stock to Buy According to Analysts? - Insider Monkey
Eli Lilly Introduces Mounjaro in India: Much Needed Breakthrough in Obesity and Diabetes Management - Elets
Eli Lilly and Co (LLY)'s Winning Formula: Financial Metrics and Competitive Strengths - GuruFocus.com
Eli Lilly Reverses Its Recent Run On Market Malaise. Is It A Sell? - Investor's Business Daily
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market - Reuters.com
Mounjaro: As Eli Lilly's blockbuster anti-obesity drug comes to India, expert lists key side effects - The Times of India
Can A Weekly Injection Fix Obesity? As Eli Lilly’s Mounjaro Enters India, Experts Weigh The Pros And Cons of Weight Loss Meds - ETV Bharat
As Eli Lilly’s popular weight loss drug enters India, doctors warn of potential misuse - The Financial Express
₹14,000 per month weight-loss shot is here to cash in on India’s obesity crisis - The Economic Times
Eli Lilly’s weight loss drug launches in India: Here are 4 things to know about Mounjaro - The Indian Express
Hello, I'm "MK Signal," an AI reporter who analyzes U.S. stock hot issues.A Buy signal for Eli Lilly.. - 매일경제
Eli Lilly launches its blockbuster weight loss drug Mounjaro in India - MSN
Eli Lilly Shares Are Up Today: What's Going On? - Benzinga
Eli Lilly’s diabetes and weight-loss drug Mounjaro debuts in India - Investing.com Australia
Lilly's weight-loss drug launch in India to energize rivals eyeing mega market - Reuters
Factbox-Lilly's weight-loss drug launch in India to energize rivals eyeing mega market - Yahoo Finance
Weight-loss drug Mounjaro now available in India: All you need to know - Business Standard
Eli Lilly beats Novo Nordisk to launch weight-loss drug Mounjaro in India, at $50 for 5 mg vial - Bilyonaryo Business News
Behind the Scenes of Eli Lilly's Latest Options Trends - Benzinga
Eli Lilly launches blockbuster anti-obesity drug Mounjaro in India. Prices here - Business Standard
Eli Lilly launches weight loss drug in India beating Novo Nordisk - Seeking Alpha
Eli Lilly Introduces Mounjaro Single-Dose Vial for Diabetes and Obesity - SMEStreet
Eli Lilly first to launch weight loss drug in obesity-hit India - BNN Bloomberg
Finanzdaten der Lilly Eli Co-Aktie (LLY)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):